[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-pressure-control\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-pressure-control":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,78,115,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100635725","development-of-a-mobile-application-called-tansiyoritim-for-hypertension-patients-100635725",false,"NCT07556419","Development of a Mobile Application Called TansiyoRitim for Hypertension Patients","The Effect of a Mobile Application Developed for Hypertension Patients on Blood Pressure Control, Treatment Adherence, and Self-Efficacy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosed with hypertension at least 1 year prior to enrollment\n* Currently using antihypertensive medication\n* Able to use a smartphone\n* Able to measure blood pressure at home\n* No severe visual or hearing impairment\n* Able to communicate in Turkish\n* Literate\n* Willing to participate and provide informed consent\n\nExclusion Criteria:\n\n* Age under 18 or over 85 years\n* Presence of severe comorbid chronic disease affecting participation\n* Severe physical or cognitive impairment preventing participation\n* Body mass index (BMI) ≥ 30 kg\u002Fm²","ALL","18 Years","85 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"NA","Based on King's Theory of Goal Success, this project is designed to develop a mobile application called TansiyoRitim for individuals over the age of 18 diagnosed with hypertension. The research consists of the following phases: creating educational content, designing the mobile application, and evaluating the application and its effectiveness. Within the scope of the research, participants' blood pressure control, self-efficacy levels, and treatment adherence behaviors will be assessed using valid and reliable measurement tools, and the goal is to support these behaviors through the developed mobile health application. Participants' clinical treatment processes, pharmacological treatment adjustments planned by the physician, and changes in medication dosages will be excluded from the scope of the project. No intervention will be made in the medical treatment currently being administered during the study; participants' routine clinical follow-up and treatment processes will continue within the framework of standard care. Only educational and mobile app-based supportive interventions will be implemented within the scope of the research.",[27,28,29,30,31],"Hypertension","Mobile Application","Blood Pressure Control","Treatment Adherence","Self-Efficacy",[27,33,34,30,31,35],"mobile application","blood pressure control","King's Goal Achievement Theory","NOT_YET_RECRUITING","2026-06-16",{"date":39,"type":40},"2026-06-18","ACTUAL",{"date":42,"type":21},"2026-07-01",{"date":44,"type":21},"2027-03-20",{"name":46,"class":47},"Kafkas University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":74,"leadSponsor":76,"locationsCount":48},"100609716","clinical-decision-support-tool-for-the-treatment-of-uncontrolled-hypertension-100609716","NCT07218198","Clinical Decision Support Tool for the Treatment of Uncontrolled Hypertension","A Stepped Wedged, Cluster Randomized Clinical Trial to Evaluate the Efficacy of a Clinical Decision Support Tool in the Treatment of Uncontrolled Hypertension","AI-HTN","Inclusion Criteria:\n\n1. Men and women 18 years of age or older\n2. Electronic Health Record (EHR) of hypertension AND prescribed at least one BP lowering medication\n3. Office systolic BP of 130 mmHg or higher\n4. Willing and able to comply with the study instructions AND attend a scheduled study visit\n\nExclusion Criteria:\n\n1. Women who are pregnant, plan to become pregnant, or are breast-feeding\n2. Know heart failure with reduced ejection fraction and a left ventricular ejection fraction of less than 40%\n3. End-stage kidney disease currently undergoing renal replacement therapy, or an eGFR \\\u003C 15ml\u002Fmin\u002F1.73m2\n4. In the opinion of the investigator, any other condition that will preclude participation in the study",{"count":58,"type":21},168,[24],"The goal of this clinical trial is to study whether having a clinical decision support (CDS) tool available to clinician use will more effectively lower BP 4 weeks after an outpatient visit compared with usual care. The main objective is to assess the impact of the CDS tool, that is embedded with the electronic medical record (EMR), that is available during outpatient clinical encounters, on blood pressure (BP) changes among participants with uncontrolled hypertension.\n\nParticipants will:\n\nVisit the clinic 4 weeks, after their initial clinician visit, for a BP check.",[27,62,63,29],"Hypertension (HTN)","Blood Pressure, High",[65,27,66,67,68,69],"Uncontrolled Hypertension","Blood Pressure","High Blood Pressure","Artificial Intelligence","AI","2026-04-27",{"date":72,"type":40},"2026-04-28",{"date":42,"type":21},{"date":75,"type":21},"2027-12-01",{"name":77,"class":47},"The Cleveland Clinic",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":99,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100636151","a-smart-phone-application-to-improve-adoption-of-the-2024-kidney-disease-improving-global-outcomes-kdigo-chronic-kidney-disease-ckd-guidelines-100636151","NCT07561957","A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines","A Smart Phone Application to Improve Adoption of the 2024 KDIGO CKD Guidelines","Inclusion Criteria:\n\n* Adults aged ≥16 years.\n* Diagnosed with CKD stages 1-5.\n* Owns a smartphone and is capable of using mobile applications.\n* Provides informed consent.\n\nExclusion Criteria:\n\n* Inability to provide informed consent due to a neurocognitive impairment.\n* Age 30 years or older\n\nThe study will be conducted in the already established SJH Young Adult Clinic, with anticipated expansion coinciding with the co-location Children's Health Ireland (CHI) on site.","16 Years","30 Years",{"count":88,"type":21},80,[24],"The goal of this study is to establish whether use of a digital intervention can improve adherence and alignment with the Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) 2024 Guidelines.\n\nA subset of the study will focus on whether the intervention improves outcomes for young adults living with CKD, in the context of the imminent co-location of Children's Health Ireland on the St. James's Hospital campus.\n\nYoung adults with CKD transitioning to adult services are recognised as a high-risk and vulnerable cohort, with many individuals unaware of increased cardiovascular risk and mortality¹². In response, and in the context of the co-location of Children's Health Ireland on the St. James's Hospital site, a young adult nephrology clinic has been established.\n\nThe KDIGO CKD 2024 Guidelines identify transition as a period of increased risk and include recommendations regarding cardiovascular risk factor targets and the use of therapies known to delay CKD progression³.\n\nElectronic communication is a preferred method for accessing health information among many young adults⁴⁵ and aligns with Sláintecare digital health strategies⁶. A recently established, award-winning St. James's Hospital renal smartphone application is currently used by over 3,000 individuals living with CKD.\n\nThe study aims to determine whether use of the application improves adherence to KDIGO guideline recommendations, with the objective of delaying CKD progression and associated complications. The application will support optimisation of care by signposting opportunities for evidence-based interventions (e.g., SGLT2 inhibitors, renin-angiotensin system inhibition) to healthcare providers. The application will also provide participants with tailored recommendations, reminders, educational materials, and collection of patient-reported outcome measures.\n\nDue to the diverse population and range of specialties at St. James's Hospital, the young adult clinic serves distinct subgroups, including individuals with sickle cell anaemia and survivors of cancer and haematological malignancies. These populations will be examined in the context of KDIGO guideline implementation, contributing to a limited international evidence base.\n\nThis research evaluates an intervention designed to improve care for adults living with chronic kidney disease.",[92,93,29,94,95,96,97,98],"Chronic Kidney Disease","Proteinuria","Congenital Anomalies of the Kidneys and Urinary Tract","Nephrotic Syndrome","Sickle-Cell Nephropathy","Tuberous Sclerosis Complex","Cancer Survivors",[100,101,102,103],"Digital Interventions","Kidney Disease","Paediatric Nephrology","Transitional Nephrology","RECRUITING","2026-04-24",{"date":107,"type":40},"2026-05-01",{"date":109,"type":40},"2026-01-14",{"date":111,"type":21},"2027-06-01",{"name":113,"class":47},"St. James's Hospital, Ireland",2,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":114},"100608985","evaluating-whether-treating-elevated-blood-pressure-in-the-inpatient-setting-impacts-patient-outcomes-100608985","NCT07208669","Evaluating Whether Treating Elevated Blood Pressure in the Inpatient Setting Impacts Patient Outcomes","Evaluating Whether Treating Elevated Blood Pressure in the Inpatient Setting Impacts Patient Outcomes: the ACT-BP Pilot","ACT-BP","Inclusion Criteria:\n\n* At the unit level: Medical units that do not typically care for patients requiring step-down care.\n\nExclusion Criteria:\n\n1. Patients less than 18\n2. Patients experiencing hypertensive emergencies or cardiac symptoms\n3. Patients with active cardiovascular events, such as\n\n   * Stroke\n   * Non-ST-elevation\n   * Myocardial infarction\n   * End-stage renal disease\n   * Patients on dialysis\n   * Those with acute decompensated heart failure\n\n3\\. Patients on the unit for more than 10 days\n\n4\\. Patients transferred in after being in the intensive care unit (ICU)\n\n5\\. Pregnant and post-partum women\n\n6\\. Patients discharged within 24 hours of admission\n\n7\\. Patients whose systolic BP remains below 160 mmHg during hospitalization.",{"count":124,"type":21},4,[24],"The vast majority of the 36.2 million individuals admitted to U.S. hospitals are diagnosed with hypertension and experience an elevated blood pressure (BP) reading during hospitalization. There are no guidelines for managing asymptomatically elevated BPs in the inpatient setting, and growing observational evidence suggests that antihypertensive medication intensification increases harm. The proposed study tests whether a unit-based intervention (ACT-BP) can reduce antihypertensive medication intensification and provides information that is scientifically necessary for designing a cluster-randomized clinical trial that identifies the impact of intensification after experiencing an asymptomatically elevated BP on patient outcomes.",[29],[129,130],"hypertension","inpatient","2026-01-06",{"date":133,"type":40},"2026-01-08",{"date":135,"type":40},"2025-11-11",{"date":137,"type":21},"2027-07-31",{"name":139,"class":47},"Elizabeth Pfoh",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":147,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":48},"100607471","prilocaine-for-sphenopalatine-ganglion-block-in-endoscopic-hypophysectomy-100607471","NCT07188987","Prilocaine for Sphenopalatine Ganglion Block in Endoscopic Hypophysectomy","Bilateral Sphenopalatine Ganglion Block Using Prilocaine Versus Lidocaine as Adjuvants to General Anesthesia During Endoscopic Hypophysectomy, Randomized Trial.","Inclusion Criteria:\n\n* Patients with pituitary adenoma undergoing endoscopic hypophysectomy.\n* ASA physical status I and II.\n* Age above 21, below 45 years.\n* Male or female\n\nExclusion Criteria:\n\n* Any patient below 21 years or above 45 years.\n* Patients suffering from any of the following conditions:\n\n  * Disturbed conscious level.\n  * Coagulation abnormalities.\n  * Poorly controlled blood pressure and\u002For heart rate.\n  * Increased intracranial tension.\n  * Liver and kidney disorders.\n* Patients on anticoagulants and\u002For NSAIDS (non-steroidal anti- inflammatory drugs\n* Patients addicted to drugs and\u002For alcohol.\n* Patients with disturbed conscious level at the end of the surgery, GCS \\>14","21 Years","45 Years",{"count":150,"type":21},54,[24],"Patients undergoing endoscopic surgeries for pituitary adenoma excision suffer from wide swings in blood pressure that might increase bleeding and interfere with the surgical field.\n\nLocal anethetic infiltration and regional nerve blocks have been used to provide better analgesia, control blood pressure and improve surgical field.\n\nLimited studies evaluated shenopalatine ganglion block in pituitary adenoma excision with promising outcomes. The proposed study will compare the efficacy of two local anesthetics, prilocaine and lidocaine, for spenopalatine ganglion block in patients undergoing endoscopic pituitary adenoma excision. Evaluating the control of the intraoperative blood pressure and analgesic sparing are the main objectives of the proposed study.",[29],[155,156,157,158],"Sphenopalatine ganglion block","Prilocaine","lidocaine","endoscopic hypophysectomy","2025-11-30",{"date":161,"type":40},"2025-12-05",{"date":163,"type":21},"2025-12-01",{"date":165,"type":21},"2026-02",{"name":167,"class":47},"Kasr El Aini Hospital"]